Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer

Bin Yang; Tingting Zhao; Baijun Dong; Wei Chen; Guanjie Yang; Jun Xie; Changcheng Guo; Ruiliang Wang; Hong Wang; Longfei Huang; Bo Peng; Wei Xue; Xudong Yao

iScience (Feb 2024)

Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer

Bin Yang,
Tingting Zhao,
Baijun Dong,
Wei Chen,
Guanjie Yang,
Jun Xie,
Changcheng Guo,
Ruiliang Wang,
Hong Wang,
Longfei Huang,
Bo Peng,
Wei Xue,
Xudong Yao

Affiliations

Bin Yang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China; Corresponding author
Tingting Zhao: Department of Urology, the Shanghai Tenth People’s Hospital, School of Medicine, School of Life Sciences and Technology, Tongji University, Shanghai, China; Research Institute, GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai, China
Baijun Dong: Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Wei Chen: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Guanjie Yang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Jun Xie: Department of Urology, Shanghai Clinical College, Anhui Medical University, Shanghai, China
Changcheng Guo: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Ruiliang Wang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Hong Wang: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Longfei Huang: Research Institute, GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai, China
Bo Peng: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Wei Xue: Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Corresponding author
Xudong Yao: Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China; Corresponding author

Journal volume & issue: Vol. 27, no. 2
p. 108931

Abstract

Read online

Summary: The clinical utility of circulating tumor DNA (ctDNA) in hormone-sensitive prostate cancer (HSPC) remains inadequately elucidated. This study presents the largest real-world cohort to conduct a concordance analysis between ctDNA and tissue-based genomic profiling in HSPC patients. The findings reveal diminished ctDNA abundance in cases with low tumor burden and demonstrate an increased concordance rate between ctDNA and tissue along with the progression of disease burden. Notably, a substantial number of exclusive genomic alterations (GAs) were identified either in ctDNA or tissue in high-volume metastatic disease. Integrating tissue and ctDNA analysis identified specific gene alterations (BRCA1, BRCA2, CDK12, TP53, PTEN, or RB1) associated with a shorter time to the progression to castration-resistant prostate cancer (CRPC), with an escalated CRPC risk correlated with cumulative GAs. This multicenter, real-world investigation underscores the complementary role of ctDNA and tissue in detecting clinically pertinent GAs, highlighting their potential integration into clinical practice for advanced prostate cancer management.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords